## Ji Zhu

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1021754/publications.pdf

Version: 2024-02-01

		201385	189595
92	2,850	27	50
papers	citations	h-index	g-index
94	94	94	4464
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer. Cell Stem Cell, 2020, 26, 17-26.e6.	5.2	404
2	Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: The risk factors and hepatic radiation tolerance. International Journal of Radiation Oncology Biology Physics, 2006, 65, 426-434.	0.4	230
3	Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Research and Clinical Practice, 2014, 106, 19-26.	1.1	156
4	Overactivated Neddylation Pathway as a Therapeutic Target in Lung Cancer. Journal of the National Cancer Institute, 2014, 106, dju083.	3.0	144
5	Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma. International Journal of Radiation Oncology Biology Physics, 2006, 65, 189-195.	0.4	140
6	The pattern and prevalence of lymphatic spread in thoracic oesophageal squamous cell carcinoma. European Journal of Cardio-thoracic Surgery, 2009, 36, 480-486.	0.6	91
7	Gut Microbiome Components Predict Response to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer: A Prospective, Longitudinal Study. Clinical Cancer Research, 2021, 27, 1329-1340.	3.2	82
8	Baseline neutrophil-lymphocyte ratio (≥2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation. Radiation Oncology, 2014, 9, 295.	1.2	75
9	Postoperative Radiotherapy Improved Survival of Poor Prognostic Squamous Cell Carcinoma Esophagus. Annals of Thoracic Surgery, 2010, 90, 435-442.	0.7	70
10	Prognostic Significance of the Metastatic Lymph Node Ratio in Node-Positive Rectal Cancer. Annals of Surgical Oncology, 2008, 15, 3118-3123.	0.7	65
11	Association between dietary nitrate and nitrite intake and site-specific cancer risk: evidence from observational studies. Oncotarget, 2016, 7, 56915-56932.	0.8	61
12	Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by <i>UGT1A1</i> Status in Patients With Locally Advanced Rectal Cancer. Journal of Clinical Oncology, 2020, 38, 4231-4239.	0.8	61
13	Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study. PLoS Medicine, 2021, 18, e1003741.	3.9	60
14	Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study. Radiation Oncology, 2014, 9, 70.	1.2	58
15	Electroacupuncture treatment for pancreatic cancer pain: AÂrandomized controlled trial. Pancreatology, 2013, 13, 594-597.	0.5	55
16	Predictive value of pretreatment lymphocyte count in stage II colorectal cancer and in high-risk patients treated with adjuvant chemotherapy. Oncotarget, 2016, 7, 1014-1028.	0.8	52
17	Prognostic value of distant metastasis sites and surgery in stage IV colorectal cancer: a population-based study. International Journal of Colorectal Disease, 2018, 33, 1241-1249.	1.0	45
18	Diffusion-weighted magnetic resonance imaging for predicting the response of rectal cancer to neoadjuvant concurrent chemoradiation. World Journal of Gastroenterology, 2013, 19, 5520.	1.4	42

#	Article	IF	Citations
19	Predicting the pathological response to neoadjuvant chemoradiation using untargeted metabolomics in locally advanced rectal cancer. Radiotherapy and Oncology, 2018, 128, 548-556.	0.3	42
20	Tolerability and outcomes of radiotherapy or chemoradiotherapy for rectal cancer in elderly patients aged 70 years and older. Radiation Oncology, 2013, 8, 86.	1.2	38
21	Application of active breathing control in 3-dimensional conformal radiation therapy for hepatocellular carcinoma: The feasibility and benefit. Radiotherapy and Oncology, 2008, 87, 439-444.	0.3	37
22	A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma. Radiation Oncology, 2013, 8, 130.	1.2	36
23	Impact of Lymph Node Ratio on the Survival of Patients with Hypopharyngeal Squamous Cell Carcinoma: A Population-Based Analysis. PLoS ONE, 2013, 8, e56613.	1.1	36
24	Circulating tumor cells: A promising marker of predicting tumor response in rectal cancer patients receiving neoadjuvant chemo-radiation therapy. Oncotarget, 2016, 7, 69507-69517.	0.8	35
25	CapOX as neoadjuvant chemotherapy for locally advanced operable colon cancer patients: a prospective single-arm phase II trial. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2016, 28, 589-597.	0.7	35
26	The Gut Microbiome Is Associated With Therapeutic Responses and Toxicities of Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients—A Pilot Study. Frontiers in Cellular and Infection Microbiology, 2020, 10, 562463.	1.8	34
27	Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance. Breast Cancer Research and Treatment, 2010, 124, 733-743.	1.1	31
28	CXCL10 mRNA expression predicts response to neoadjuvant chemoradiotherapy in rectal cancer patients. Tumor Biology, 2014, 35, 9683-9691.	0.8	28
29	Accelerated hyperfractionated intensity-modulated radiotherapy for recurrent/unresectable rectal cancer in patients with previous pelvic irradiation: results of a phase II study. Radiation Oncology, 2014, 9, 278.	1.2	28
30	MicroRNA-223 Enhances Radiation Sensitivity of U87MG Cells InÂVitro and InÂVivo by Targeting Ataxia Telangiectasia Mutated. International Journal of Radiation Oncology Biology Physics, 2014, 88, 955-960.	0.4	27
31	Radiosensitization of Human Colorectal Cancer Cells by MLN4924. Technology in Cancer Research and Treatment, 2016, 15, 527-534.	0.8	26
32	Pembrolizumab for Advanced Urothelial Carcinoma. New England Journal of Medicine, 2017, 376, 2302-2304.	13.9	26
33	Prediction of Treatment Outcome by CD44v6 After Total Mesorectal Excision in Locally Advanced Rectal Cancer. Cancer Journal (Sudbury, Mass), 2008, 14, 54-61.	1.0	25
34	Prognosis of three histological subtypes of colorectal adenocarcinoma: A retrospective analysis of 8005 Chinese patients. Cancer Medicine, 2019, 8, 3411-3419.	1.3	25
35	Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT. BMC Cancer, 2019, 19, 606.	1.1	23
36	CAPIRI-IMRT: a phase II study of concurrent capecitabine and irinotecan with intensity-modulated radiation therapy for the treatment of recurrent rectal cancer. Radiation Oncology, 2015, 10, 57.	1.2	21

#	Article	IF	CITATIONS
37	Is there a prognostic value of tumor location among Chinese patients with colorectal cancer?. Oncotarget, 2017, 8, 38682-38692.	0.8	21
38	Prognostic risk factors in patients with bone metastasis from colorectal cancer. Tumor Biology, 2016, 37, 16127-16134.	0.8	20
39	Tumour diameter is a predictor of mesorectal and mesenteric lymph node metastases in anorectal melanoma. Colorectal Disease, 2013, 15, 1086-1092.	0.7	19
40	Risk of Pneumonitis Associated with Programmed Cell Death 1 Inhibitors in Cancer Patients: A Meta-analysis. Molecular Cancer Therapeutics, 2017, 16, 1588-1595.	1.9	18
41	The advantage of circulating tumor cells over serum carcinoembryonic antigen for predicting treatment responses in rectal cancer. Future Oncology, 2013, 9, 1489-1500.	1.1	17
42	The Impact of Chemotherapy Completion on the Efficacy of Irinotecan in the Preoperative Chemoradiotherapy of Locally Advanced Rectal Cancer: An Expanded Analysis of the CinClare Phase III Trial. Clinical Colorectal Cancer, 2020, 19, e58-e69.	1.0	15
43	Phase II trial of first-line chemoradiotherapy with intensity-modulated radiation therapy followed by chemotherapy for synchronous unresectable distant metastases rectal adenocarcinoma. Radiation Oncology, 2013, 8, 10.	1.2	14
44	Implications for determining the optimal treatment for locally advanced rectal cancer in elderly patients aged 75 years and older. Oncotarget, 2015, 6, 30377-30383.	0.8	13
45	Prediction of Radiation Induced Liver Disease Using Artificial Neural Networks. Japanese Journal of Clinical Oncology, 2006, 36, 783-788.	0.6	12
46	Genotype-driven phase I study of weekly irinotecan in combination with capecitabine-based neoadjuvant chemoradiation for locally advanced rectal cancer. Radiotherapy and Oncology, 2018, 129, 143-148.	0.3	12
47	Prognostic Inflammatory Index Based on Preoperative Peripheral Blood for Predicting the Prognosis of Colorectal Cancer Patients. Cancers, 2021, 13, 3.	1.7	12
48	Adjuvant therapy for T3NO rectal cancer in the total mesorectal excision era-identification of the high risk patients. Radiation Oncology, 2010, 5, 118.	1.2	11
49	A two-step method to improve image quality of CBCT with phantom-based supervised and patient-based unsupervised learning strategies. Physics in Medicine and Biology, 2022, 67, 084001.	1.6	11
50	Long-course neoadjuvant chemoradiotherapy with versus without a concomitant boost in locally advanced rectal cancer: a randomized, multicenter, phase II trial (FDRT-002). Radiation Oncology, 2019, 14, 215.	1.2	10
51	Prognostic Values of Preoperative Inflammatory and Nutritional Markers for Colorectal Cancer. Frontiers in Oncology, 2020, 10, 585083.	1.3	10
52	TNF rs1799964 as a Predictive Factor of Acute Toxicities in Chinese Rectal Cancer Patients Treated With Chemoradiotherapy. Medicine (United States), 2015, 94, e1955.	0.4	9
53	Lymph node ratio (LNR) as a complementary staging system to TNM staging in salivary gland cancer. European Archives of Oto-Rhino-Laryngology, 2019, 276, 3425-3434.	0.8	9
54	The role of nutritional assessment for predicting radiotherapy-induced adverse events in patients with gastric cancer. British Journal of Radiology, 2022, 95, 20201004.	1.0	9

#	Article	IF	CITATIONS
55	Genetic polymorphisms of PAI-1 and PAR-1 are associated with acute normal tissue toxicity in Chinese rectal cancer patients treated with pelvic radiotherapy. OncoTargets and Therapy, 2015, 8, 2291.	1.0	8
56	Poorer prognosis in young female patients with non-metastatic colorectal cancer: a hospital-based analysis of 5,047 patients in China. Cancer Management and Research, 2018, Volume 10, 653-661.	0.9	8
57	<p>Knockdown Of TRIM31 Enhances Colorectal Cancer Radiosensitivity By Inducing DNA Damage And Activating Apoptosis</p> . OncoTargets and Therapy, 2019, Volume 12, 8179-8188.	1.0	8
58	An expansion study of genotype-driven weekly irinotecan and capecitabine in combination with neoadjuvant radiotherapy for locally advanced rectal cancer with UGT1A1 *1*1 genotype. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481985229.	1.4	8
59	A multicenter randomized phase III trial of capecitabine with or without irinotecan driven by UGT1A1 in neoadjuvant chemoradiation of locally advanced rectal cancer (CinClare) Journal of Clinical Oncology, 2019, 37, 3510-3510.	0.8	8
60	Implications for selecting local excision in locally advanced rectal cancer after preoperative chemoradiation. Oncotarget, 2015, 6, 11714-11722.	0.8	8
61	YpT1-2N0 rectal cancer after neoadjuvant chemoradiation has lower survival compared with pT1-2N0 rectal cancer. Oncotarget, 2015, 6, 41056-41062.	0.8	8
62	Adjuvant therapy in resectable gastric cancerâ€"the CRITICS trial. Lancet Oncology, The, 2018, 19, e330.	5.1	7
63	Negative to positive lymph node ratio is a superior predictor than traditional lymph node status in stage III colorectal cancer. Oncotarget, 2016, 7, 72290-72299.	0.8	7
64	BH3 mimetic ABT-737 sensitizes colorectal cancer cells to ixazomib through MCL-1 downregulation and autophagy inhibition. American Journal of Cancer Research, 2016, 6, 1345-57.	1.4	7
65	Sex, Race, and Age Disparities in the Improvement of Survival for Gastrointestinal Cancer over Time. Scientific Reports, 2016, 6, 29655.	1.6	6
66	Reevaluation of laparoscopic surgery's value in pathological T4 colon cancer with comparison to open surgery: A retrospective and propensity score-matched study. International Journal of Surgery, 2018, 53, 12-17.	1.1	6
67	T3 subclassification using the EMD/mesorectum ratio predicts neoadjuvant chemoradiation outcome in T3 rectal cancer patients. British Journal of Radiology, 2018, 91, 20170617.	1.0	6
68	Predicting treatment outcome of rectal cancer patients underwent neoadjuvant chemoradiotherapy by ctDNA: The potential use of ctDNA monitoring as organ-sparing approach Journal of Clinical Oncology, 2018, 36, 3608-3608.	0.8	6
69	A Simple Scoring System Based on Clinical Features to Predict Locally Advanced Rectal Cancers. Journal of Gastrointestinal Surgery, 2009, 13, 1299-1305.	0.9	5
70	A Novel Prognostic Model Incorporating Carcinoembryonic Antigen in 3-Week or Longer Postoperative Period for Stage III Colon Cancer: A Multicenter Retrospective Study. Frontiers in Oncology, 2020, 10, 566784.	1.3	5
71	The HELOISE Study: Concerns About Trial Design. Journal of Clinical Oncology, 2018, 36, 302-302.	0.8	4
72	Aneuploidy of chromosome 8 and mutation of circulating tumor cells predict pathologic complete response in the treatment of locally advanced rectal cancer. Oncology Letters, 2018, 16, 1863-1868.	0.8	4

#	Article	IF	CITATIONS
73	Survival Benefit of Preoperative Versus Postoperative Radiotherapy in Metastatic Rectal Cancer Treated With Definitive Surgical Resection of Primary Tumor: A Population Based, Propensity Score-Matched Study. Journal of Cancer, 2019, 10, 1307-1312.	1.2	4
74	ACRNaCT trial protocol: efficacy of adjuvant chemotherapy in patients with clinical T3b/T4, N+ rectal Cancer undergoing Neoadjuvant Chemoradiotherapy: a pathology-oriented, prospective, multicenter, randomized, open-label, parallel group clinical trial. BMC Cancer, 2019, 19, 1117.	1.1	4
75	Development and validation of a novel classification scheme for combining pathological T stage and log odds of positive lymph nodes for colon cancer. European Journal of Surgical Oncology, 2022, 48, 228-236.	0.5	4
76	ctDNA as a potential prognostic marker for locally advanced rectal cancer patients with †watch and wait†approach Journal of Clinical Oncology, 2019, 37, 3544-3544.	0.8	4
77	Postoperative Chemoradiotherapy Combined with Epirubicin-Based Triplet Chemotherapy for Locally Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction. PLoS ONE, 2013, 8, e54233.	1.1	4
78	Screening and validation of a novel T stage-lymph node ratio classification for operable colon cancer. Annals of Translational Medicine, 2021, 9, 1513-1513.	0.7	4
79	Use of olaparib in patients with advanced gastric cancer. Lancet Oncology, The, 2018, 19, e75.	5.1	3
80	Evaluating the Effect of Lymph Node Status on Survival in Large Colon Cancer. Frontiers in Oncology, 2018, 8, 602.	1.3	3
81	Association Between Three-Dimensional Transrectal Ultrasound Findings and Tumor Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer: An Observational Study. Frontiers in Oncology, 2021, 11, 648839.	1.3	3
82	HER2-targeted regimens after prior trastuzumab for patients with HER2-positive unresectable, locally advanced or metastatic breast cancer: a network meta-analysis of randomized controlled trials. Annals of Translational Medicine, 2020, 8, 1634-1634.	0.7	3
83	<p>A novel LARCassigner3 classification predicts outcomes in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy: a retrospective training and validation analysis</p> . Cancer Management and Research, 2019, Volume 11, 4153-4170.	0.9	2
84	An atlas-guided automatic planning approach for rectal cancer intensity-modulated radiotherapy. Physics in Medicine and Biology, 2021, 66, 155011.	1.6	2
85	Whole brain radiotherapy for non-small cell lung cancer. Lancet, The, 2017, 389, 1395.	6.3	1
86	Short-course radiotherapy with delayed surgery for rectal cancer. Lancet Oncology, The, 2017, 18, e294.	5.1	1
87	Adjuvant chemotherapy for patients with ypT0-2N0-category after neoadjuvant chemoradiotherapy for rectal cancer. Molecular and Clinical Oncology, 2017, 7, 864-868.	0.4	1
88	Problematic Landmark Analysis Has Led to a Problematic Conclusion. Journal of Clinical Oncology, 2017, 35, 1967-1968.	0.8	1
89	GRECCAR2 trial: details worthy of more attention. Lancet, The, 2018, 391, 122.	6.3	1
90	Prophylactic cranial irradiation in small-cell lung cancer. Lancet Oncology, The, 2017, 18, e368.	5.1	0

#	Article	IF	CITATIONS
91	Pelvic recurrence after definitive surgery for locally advanced rectal cancer: a retrospective investigation of implications for precision radiotherapy field design. Oncotarget, 2017, 8, 95973-95980.	0.8	O
92	Watch and wait approach following neoadjuvant chemoradiotherapy for rectal cancer patients: A single-centre experience Journal of Clinical Oncology, 2019, 37, 681-681.	0.8	0